Sugi Predict
/ Targets
/ SULT2A1
Top predicted compounds (top 20 by supporting neighbours, then confidence)
Clinical trials — most relevant to SULT2A1 by text similarity (a relevance ranking, not an exhaustive list)
| Trial | Phase | Status |
|---|
| The Role of CYP8B1 Polymorphisms in Modulating the Biochemical Pathways Affected by SGLT2 Inhibitors in T2DM and Obesity |
PHASE4 | COMPLETED |
| Comparison of Two Different Doses of Paracetamol for Post-Operative Pain Relief |
PHASE4 | COMPLETED |
| Pharmacogenetics of Nicotine Addiction Treatment |
PHASE3 | COMPLETED |
| Tamoxifen Citrate in Treating Patients With Metastatic or Recurrent Breast Cancer |
PHASE2 | COMPLETED |
| Activity of Regorafenib in Combination With Chemotherapy in Patients With Advanced Biliary Tract Cancer |
PHASE1/PHASE2 | COMPLETED |
| Variability of Sulfotransferase 1A1 Activity in Humans: an Approach to Improve Predictive Drug Response - Part I: Analysis of Intraindividual Variation in Healthy Adults |
PHASE1 | COMPLETED |
| Variability of Sulfotransferase Activity in Humans: an Approach to Improve Predictive Drug Response Part II: Analysis of Interindividual Variation in Hypertensive Patients |
PHASE1 | COMPLETED |
| 2-Methoxyestradiol in Treating Patients With Advanced Solid Tumors |
PHASE1 | COMPLETED |
| Pharmacokinetics, Metabolism and Analgesic Effects of Flupirtine |
PHASE1 | COMPLETED |
| Abacavir Pharmacokinetic Study in the Absence/Presence of Darunavir/Ritonavir or Raltegravir in HIV-infected Subjects |
PHASE1 | COMPLETED |
| Atazanavir/Ritonavir and Darunavir/Ritonavir PK Tail Study |
PHASE1 | COMPLETED |
| Bioavailability of Paracetamol, Amoxicillin and Talinolol Before, Immediately and One Year After Gastric Bypass Operation |
PHASE1 | COMPLETED |
| PK of Tenofovir, Emtricitabine and Efavirenz in Healthy Volunteers |
PHASE1 | COMPLETED |
| Pharmacokinetics (PK) Study of Once Daily Darunavir/Ritonavir and Twice and Once Daily Raltegravir in HIV-infected Subjects |
PHASE1 | COMPLETED |
| Pharmacokinetics of Benzo[a]Pyrene: Impact of Diet |
EARLY_PHASE1 | COMPLETED |
| Contribution of UGT2B17 to the Pharmacokinetics of Diclofenac |
EARLY_PHASE1 | RECRUITING |
| Tamoxifen in Women With Breast Cancer and in Women at High-Risk of Breast Cancer Who Are Receiving Venlafaxine, Citalopram, Escitalopram, Gabapentin, or Sertraline |
nan | COMPLETED |
| APAP Hepatotoxicity After Therapeutic Doses |
nan | UNKNOWN |
| Genetic Polymorphisms in UGT1A6 and UGT2B7 in Asian Population: Association With Lung Cancer Phenotype |
nan | UNKNOWN |
| The Clinical and Economic Impact of Pharmacogenomic Testing for Tamoxifen Metabolism in Postmenopausal Women Receiving Tamoxifen for Prevention of Recurrent Breast Cancer |
nan | COMPLETED |
| A Pilot Study of Varying Doses of Tamoxifen in the Setting of Genetic Polymorphisms of CYP2D6 |
nan | COMPLETED |
| Natural History Study to Determine Drug Metabolism Phenotype and Appropriate Germline Source DNA in Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplant |
nan | RECRUITING |
| Aromatase Inhibitor Clinical Trial |
nan | UNKNOWN |
| Measurement of Risperidone and 9-Hydroxyrisperidone in Plasma and Saliva |
nan | COMPLETED |
| Studying Urine and Blood Samples in Women With Newly Diagnosed Breast Cancer |
nan | COMPLETED |
| Individualized Antiretroviral Therapy |
nan | COMPLETED |
| Pharmacogenetics of Anastrozole in Postmenopausal Women With Estrogen Receptor-Positive and/or Progesterone Receptor-Positive Stage I, Stage II, or Stage III Breast Cancer |
nan | COMPLETED |
| Effects of Genotype on CYP2C9 Drug Interactions |
nan | COMPLETED |
| Pharmacogenetic Determinants Of Treatment Response In Children |
nan | RECRUITING |
| Genetic Study of Patients Previously Treated With Flavopiridol on Clinical Trial NCI-97-C-0171C |
nan | COMPLETED |
Related proteins — ESM-2 sequence neighbours (a SULT2A1 binder may also engage these)